Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Hagop M. Kantarjian, Naval Daver et al.|The Lancet Haematology|2018Cited by 273
Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNicholas J. Short, Elias Jabbour, Hagop M. Kantarjian et al.|Blood|2019Cited by 39